Results 81 to 90 of about 26,198 (235)

Allopurinol does not enhance antioxidant properties of extracellular fluid

, 1988
Allopurinol has been shown to provide significant protection against ischemia/reperfusion-induced microvascular and parenchymal cell injury. It has been hypothesized that the protection seen with allopurinol after ischemia/reperfusion (I/R) is caused by
B. J. Zimmerman, D. A. Parks, M. B. Grisham, D. N. Granger   +3 more
core   +1 more source

HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol [PDF]

Clinical and Experimental Pediatrics
Background Allopurinol is widely used to prevent hyperuricemia in patients with tumor lysis syndrome. However, its use can trigger severe cutaneous adverse reactions (SCARs) with a mortality rate of approximately 11.39%. The human leukocyte antigen (HLA)–
Parisa Maneechai, Cholada Ratanatharathron, Jassada Buaboonam, Kleebsabai Sanpakit   +3 more
doaj   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Primary Extramedullary Acute Promyelocytic Leukemia Presenting as Cauda Equina Syndrome: A Rare Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT APL presenting as an extramedullary mass is exceedingly rare. Here, we describe extramedullary APL causing cauda equina syndrome, underscoring the diagnostic challenges associated with an atypical presentation, highlighting the complexity of distinguishing extramedullary APL from other conditions, and discussing the stepwise approach to ...
Amir Ali, Marc Ringor, Arbab Khalid, Diana Garcia, Ravishankar Konchada, Ramalingam Ratnasabapathy, Yuna Chae, Arman Melikyan, George Yaghmour   +8 more
wiley   +1 more source

Allopurinol improves endothelial dysfunction in chronic heart failure

, 2002
Background— Increased oxidative stress in chronic heart failure is thought to contribute to endothelial dysfunction. Xanthine oxidase produces oxidative stress and therefore we examined whether allopurinol improved endothelial dysfunction in chronic ...
Belch, Jill J. F.; id_orcid, Colin A.J. Farquharson, Robert Butler, Farquharson, Colin A. J., Hill, Alexander, Allan D. Struthers, Struthers, Allan D., Jill J.F. Belch, Butler, Robert, Alexander Hill   +9 more
core   +1 more source

Validasi Metode Penentuan Tablet Allopurinol Menggunakan Spektrofotometri Ultraviolet dalam Larutan Asam

Jurnal Kimia Sains dan Aplikasi, 2019
Allopurinol sebagai obat tablet banyak beredar di pasaran, sehingga kadar allopurinol haruslah memenuhi persyaratan agar kualitas obat dijamin. Pada penelitian ini, validasi metode penentuan obat tablet allopurinol dalam tiga konsentrasi HCl, yaitu 0,05 ...
Suprianto Suprianto, Ihsanul Hafiz, Hendri Faisal, Hasrat Masa Harefa   +3 more
doaj   +1 more source

Rate Versus Rhythm Control in a Multimorbid Patient With Tachy–Brady Syndrome: Evaluation of Clinical Outcomes and Pacing Dependency

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT This case report describes a 77‐year‐old man with multiple comorbidities, including atrial fibrillation, heart failure with mildly reduced ejection fraction, hypertension, diabetes mellitus, and prior coronary artery bypass grafting, who presented with severe hypertension and dyspnoea.
Reem Fakak, Emma Nordahl, Joseph Moutiris   +2 more
wiley   +1 more source

Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia

, 2000
PURPOSE: To tabulate data obtained over a 21-year period to determine the efficacy and safety of an intravenous (IV) allopurinol preparation. PATIENTS AND METHODS: IV allopurinol was provided on a compassionate plea basis to patients of any age in whom
Richard V. Smalley, Susan A. Anderson, John A. Hohneker, Sandra Haase-Statz, Donna Cederberg, Al Guaspari   +5 more
core   +1 more source

Effects of allopurinol and febuxostat on uric acid transport and transporter expression in human umbilical vein endothelial cells.

PLoS ONE
Uric acid induces radical oxygen species formation, endothelial inflammation, and endothelial dysfunction which contributes to the progression of atherosclerosis.
Karel H van der Pol, Jan Koenderink, Jeroen J M W van den Heuvel, Petra van den Broek, Janny Peters, Imke D W van Bunningen, Jeanne Pertijs, Frans G M Russel, Jim Koldenhof, Wim J Morshuis, Joris van Drongelen, Tom J J Schirris, Andries van der Meer, Gerard A Rongen   +13 more
doaj   +1 more source

Randomized Controlled Trial of Herbal Extracts (Eugenia polyantha, Apium graveolens, Nigella sativa) and Allopurinol Effect on Serum Uric Acid, Urinary Uric Acid and High Sensitivity C-Reactive Protein Levels in Subject with Hyperuricemia

Indonesian Journal of Rheumatology, 2019
Background: Eugenia polyantha, Apium graveolens, and Nigella sativa are extracts which in preclinical trial can reduce uric acid serum, increase urinary uric acid excretion. Allopurinol is an inhibitor of the xanthine oxidase enzyme which can also reduce
Bantar Sutoko, Rakhma Yanti Hellmi, Ika Vemillia W, Stepanus Agung L   +3 more
doaj   +1 more source